O Protocolo para Sarcopenia Que Não Existe: Uma Checagem de 3 Estudos

The Claim

Peptides and resistance training can beat sarcopenia — the progressive, age-related muscle loss that quietly dismantles independence across millions of older adults. The implication: we have the evidence, we have the tools, here's your protocol.

Spoiler: none of that is true. At least not based on these three papers.

The Papers Under Review

Three studies were grouped together to build this narrative:

• Compensatory Movement Strategies during the Rearfoot Elevated Split Squat after ACL Reconstruction — Medicine & Science in Sports & Exercise
• Tensiomyography-derived contractile parameters in sarcopenic and non-sarcopenic older adults — Frontiers in Aging
• Ghrelin attenuates skeletal-muscle atrophy by regulating muscle protein degradation and lung inflammation in aged male mice with lipopolysaccharide-induced lung injury — Peptides

Combined average evidence score: 4.0 out of 10. At that tier, the correct move is to say "interesting preliminary signal worth studying further" — not "here's your protocol."

Paper 1: The ACL Study That Has Nothing to Do with Sarcopenia

The ACL reconstruction study enrolled 25 participants recovering from anterior cruciate ligament surgery. Researchers tracked how these individuals compensated mechanically during the rearfoot elevated split squat in the months following surgical repair.

This is legitimate sports medicine research. Understanding compensatory movement patterns during post-surgical rehab is genuinely valuable for physical therapists and orthopedic clinicians.

For sarcopenia? This paper has nothing to offer. ACL reconstruction patients are typically younger adults recovering from a traumatic injury — not elderly individuals experiencing the slow, systemic erosion of muscle mass that defines sarcopenia. Grouping this study into a sarcopenia evidence cluster isn't a minor classification error. It signals the topic group was assembled without a coherent evidentiary strategy. When one of your three papers is simply in the wrong room, the whole argument is already in trouble.

Paper 2: A Diagnostic Tool You'll Never Have Access To

The tensiomyography study is, at least, actually about sarcopenia. Researchers applied tensiomyography — a specialized device that measures muscle contractility via skin-surface electrical impulses — to both sarcopenic and non-sarcopenic older adults. The key finding: tensiomyography-derived parameters could detect functional impairment that standard assessments like handgrip strength and DXA-based muscle mass measurements sometimes miss.

That's genuinely interesting. If validated further across larger cohorts, earlier detection could allow clinicians to intervene before significant function is lost.

But here's the wall: tensiomyography devices cost tens of thousands of dollars and are not standard clinical equipment. This paper tells you a specialized machine that you and your doctor don't have might catch sarcopenia earlier than the tools you already use. It offers no treatment. No intervention. No protocol. For anyone trying to preserve or rebuild muscle with age, this paper ends exactly where the useful part would begin.

Paper 3: Ghrelin, Septic Mice, and a Very Long Leap

The ghrelin study is where the evidence gap becomes most glaring. Researchers administered ghrelin — a peptide hormone primarily known for stimulating hunger — to aged male mice that had been given lipopolysaccharide (LPS)-induced lung injury, an artificially induced septic state. The result: ghrelin reduced muscle protein degradation and attenuated lung inflammation in these animals.

Mechanistically plausible. Ghrelin has documented anti-inflammatory and anabolic signaling properties. The study is internally coherent.

The problem is the leap from this result to any human recommendation. For that leap to hold, all of the following have to be true:

• The mechanism translates cleanly from mice to humans — the majority of rodent models don't survive this test
• The effect occurs in the absence of an acute septic event, not just during one (this study specifically examined a disease state, not normal aging)
• A delivery method, dose, and human safety profile exist — none are provided by this paper
• The effect is clinically meaningful at doses achievable outside a controlled lab setting

The paper itself claims none of this. It's a mechanistic mouse study pointing toward a hypothesis worth testing in humans someday. The problem isn't the study — it's using it to anchor a practical treatment claim it was never designed to support. The paper also had unclear control group descriptions, which compounds the uncertainty further.

What Would Actually Be Convincing

This isn't an unreasonable bar. It's the minimum required before making a treatment claim:

• A randomized controlled trial in older humans — not mice
• Testing a specific intervention (ghrelin analog, resistance protocol, targeted peptide) against a control group
• Pre-registered primary outcomes: muscle mass, functional strength, fall risk
• At least 6 months of follow-up to capture clinically meaningful sarcopenia-relevant changes
• Independent replication in at least one additional cohort

None of that exists here. What does have strong, replicated evidence for sarcopenia management? Progressive resistance training, consistently demonstrated across multiple high-quality RCTs in older adults. Adequate protein intake — particularly leucine-rich sources — combined with resistance exercise. Not exciting. Not a peptide protocol. Effective.

The Verdict

This is not a sarcopenia evidence base. It's three papers sharing adjacent keywords, assembled into a cluster that implies a protocol none of them support. One studies post-surgical knee patients. One studies a diagnostic device clinicians don't have. One studies a hunger peptide injected into septic elderly mice.

Average evidence score: 4.0 out of 10.

The problem with most biohacking content isn't that the science is fabricated. It's that real science gets stretched to carry conclusions it was never designed to support. That gap is where most bad health advice lives.

A score of 4.0 means: keep studying this. It does not mean: here's your protocol. Sarcopenia is a real and serious condition. It deserves better evidence than this.